Skip Navigation
Skip to contents
Filter

ARTICLE TYPE

more+
SELECT FILTER
 
Close

PUBLICATION DATE

15 results
Display

Erratum: Basic Findings Regarding Breast Cancer in Korea in 2015: Data from a Breast Cancer Registry

Kang SY, Kim YS, Kim Z, Kim HY, Lee SK, Jung KW, Youn HJ, Korean Breast Cancer Society

This article was initially published on the Journal of Breast Cancer with a misspelled legend display in Figure 3. The postmenopause and premenopause should be changed with each other.
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Neoadjuvant Therapy Should Be the Standard of Care for Every Node Positive Breast Cancer Patient

Hamdy O

No abstract available.
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Durable Response of Androgen Receptor-Positive Male Breast Cancer to Goserelin

Abdel Azim H, Kassem L, Shohdy KS, Eshaak B, Anis SE, Kamal NS

The luteinizing hormone-releasing hormone/androgen receptor (LHRH/AR) pathway is a promising treatment target in a subgroup of female patients with triple-negative breast cancer (TNBC). However, very little is known about the...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Whole Exome Sequencing in the Accurate Diagnosis of Bilateral Breast Cancer: a Case Study

Li X, Yang M, Zhang Q, Fan Y, Zhu T, Chen F, Wang K

When faced with a case of bilateral breast cancer (BBC), understanding how to differentiate bilateral primary breast cancer from contralateral metastatic breast cancer is essential for treatment, but clear identification...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Central Nervous System Failure in Korean Breast Cancer Patients with HER2-Enriched Subtype: Korean Radiation Oncology Group 16-15 Multicenter Retrospective Study

Kim K, Shin KH, Kim JH, Choi DH, Park W, Kim YB, Kim HJ, Kim JH, Park H, Lee SY, Kim J, Oh DH, Kim IA

PURPOSE: The purpose of this study was to evaluate the risk of central nervous system (CNS) failure in Korean patients with human epidermal growth factor receptor 2 (HER2)-enriched breast cancer...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Immediate Breast Reconstruction Does Not Have a Clinically Significant Impact on Adjuvant Treatment Delay and Subsequent Survival Outcomes

Baek SH, Bae SJ, Yoon CI, Park SE, Cha CH, Ahn SG, Kim YS, Roh TS, Jeong J

PURPOSE: The use of immediate breast reconstruction (IBR) has been debated because it may be a causative factor in adjuvant treatment delay and may subsequently increase the probability of recurrence....
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Young Patients with Hormone Receptor-Positive Breast Cancer Have a Higher Long-Term Risk of Breast Cancer Specific Death

Fu J, Zhong C, Wu L, Li D, Xu T, Jiang T, Yang J, Du J

PURPOSE: Although it is widely accepted that hormone receptor (HR) status is associated with later post-diagnostic periods, a debate exists as to whether the association is independent of age. The...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Prescription Refill Gap of Endocrine Treatment from Electronic Medical Records as a Prognostic Factor in Breast Cancer Patients

Lee Y, Park YR, Lee JS, Lee SB, Chung IY, Son BH, Ahn SH, Lee JW

PURPOSE: Discontinuation of hormone therapy is known to lead to a poorer prognosis in breast cancer patients. We aimed to investigate the prescription gap as a prompt index of medication...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
CD9 Expression in Tumor Cells Is Associated with Poor Prognosis in Patients with Invasive Lobular Carcinoma

Baek J, Jang N, Choi JE, Kim JR, Bae YK

PURPOSE: We investigated the prognostic significance of CD9 expression in tumor cells of patients with invasive lobular carcinoma (ILC). METHODS: CD9 expression was evaluated by immunohistochemistry in 113 ILC tissue samples....
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Determining Whether High Nodal Burden in Early Breast Cancer Patients Can Be Predicted Preoperatively to Avoid Sentinel Lymph Node Biopsy

Lim GH, Teo SY, Allen JC, Chinthala , Leong LC

PURPOSE: The Z0011 trial showed that axillary lymph node dissection (ALND) can be safely avoided in breast cancer patients with low nodal burden (LNB). ALND can be performed in patients...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Screening of Recurrence Related MicroRNA in Ductal Carcinoma In Situ and Functional Study of MicroRNA-654-5p

Li S, Pu T, Xiao L, Gao H, Li L, Ye F, Liu Y, Bu H

PURPOSE: Ductal carcinoma in situ (DCIS) contributes to 20%–30% of newly diagnosed cases of breast cancer in China. Although the breast cancer-specific mortality of DCIS is extremely low, a small...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Tumor-Associated Macrophages as Potential Prognostic Biomarkers of Invasive Breast Cancer

Jeong H, Hwang I, Kang SH, Shin HC, Kwon SY

PURPOSE: Tumor-associated macrophages (TAMs) are activated macrophages associated with tumor progression in various cancers. TAMs can polarize M1 or M2 type. M1 has a pro-inflammatory function and kills pathogens. Conversely,...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Circulating Plasmacytoid and Myeloid Dendritic Cells in Breast Cancer Patients: A Pilot Study

Paek SH, Kim HG, Lee JW, Woo J, Kwon H, Kim JB, Lim W, Kim JR, Moon BI, Paik NS

PURPOSE: Dendritic cells (DC) are a class of bone marrow-derived cells found in the blood, epithelia, and lymphoid tissues, and are the most efficient antigen presenting cells. The number and...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Pokemon Inhibits Transforming Growth Factor β-Smad4-Related Cell Proliferation Arrest in Breast Cancer through Specificity Protein 1

Chen L, Zhong J, Liu JH, Liao DF, Shen YY, Zhong XL, Xiao X, Ding WJ, Peng XD, Xiong W, Zu XY

PURPOSE: Pokemon, also known as ZBTB7A, belongs to the POZ and Krüppel (POK) family of transcription repressors and is implicated in tumor progression as a key proto-oncogene. This present study...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
BRCA1 and Breast Cancer: a Review of the Underlying Mechanisms Resulting in the Tissue-Specific Tumorigenesis in Mutation Carriers

Semmler L, Reiter-Brennan C, Klein A

Since the first cloning of BRCA1 in 1994, many of its cellular interactions have been elucidated. However, its highly specific role in tumorigenesis in the breast tissue—carriers of BRCA1 mutations...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close

Go to Top

Copyright © 2021 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr